Albert David Limited
NSE: ALBERTDAVD
NSE
802.80
-19.00 (-2.31%)
Prev Close
821.8
Open Price
810.05
Volume
4,217
Today Low / High
800.15 / 816.55
52 WK Low / High
762.6 / 1753.95
Range
763 - 843
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 802.8, with a change of -19 (-2.312%). The expected target range on the NSE is between 763 - 843. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
09 May
810.05
-0.60%
08 May
818.45
0.41%
07 May
786.45
2.62%
06 May
854.00
-4.58%
05 May
825.00
2.06%
02 May
815.00
2.06%
30 Apr
840.00
-1.70%
29 Apr
833.65
0.86%
28 Apr
845.55
-0.79%
25 Apr
882.80
-4.25%
24 Apr
879.80
-0.28%
23 Apr
876.00
-0.43%
22 Apr
865.25
1.08%
21 Apr
851.70
2.42%
17 Apr
858.50
-0.79%
16 Apr
849.00
-0.38%
15 Apr
803.45
5.00%
11 Apr
799.00
-0.93%
Albert David Limited Graph
Albert David Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Albert David Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 802.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 802.80 | 810.83 | 729.75 - 891.91 |
| 818.86 | 655.08 - 982.63 | ||
| 826.88 | 578.82 - 1,074.95 | ||
| Bearish Scenario | 802.80 | 794.77 | 715.29 - 874.25 |
| 786.74 | 629.40 - 944.09 | ||
| 778.72 | 545.10 - 1,012.33 |
Overview of Albert David Limited
ISIN
INE155C01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
10,780
Market Cap
4,581,708,048
Last Dividend
11.5
Official Website
IPO Date
2016-06-14
DCF Diff
-1,130.34
DCF
1,933
Financial Ratios Every Investor Needs
Stock Dividend of ALBERTDAVD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-08-02 | August 02, 24 | 11.5 | 11.5 | 2024-08-02 | 2024-09-08 | |
| 2023-08-02 | August 02, 23 | 9 | 9 | 2023-08-03 | 2023-09-09 | |
| 2022-08-01 | August 01, 22 | 9 | 9 | 2022-08-02 | 2022-09-08 | |
| 2021-09-06 | September 06, 21 | 6 | 6 | 2021-09-07 | 2021-10-14 | |
| 2020-03-13 | March 13, 20 | 7 | 7 | 2020-03-16 | 2020-04-02 | 2020-03-03 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 360.26 Cr | 128.40 Cr | 231.86 Cr | 0.6436 | 1.95 Cr | 89.14 Cr | 133.45 Cr | 75.42 Cr | 132.15 | 104.54 Cr | 0.2093 |
| 2023-03-31 | 341.56 Cr | 123.09 Cr | 218.48 Cr | 0.6396 | 1.90 Cr | 49.74 Cr | 36.24 Cr | 36.17 Cr | 63.39 | 59.87 Cr | 0.1059 |
| 2022-03-31 | 312.43 Cr | 117.52 Cr | 194.91 Cr | 0.6239 | 1.60 Cr | 35.56 Cr | 31.99 Cr | 35.26 Cr | 61.78 | 56.78 Cr | 0.1129 |
| 2021-03-31 | 246.31 Cr | 88.03 Cr | 158.29 Cr | 0.6426 | 1.53 Cr | 28.94 Cr | 10.92 Cr | 22.14 Cr | 38.80 | 36.46 Cr | 0.0899 |
| 2020-03-31 | 318.43 Cr | 107.99 Cr | 210.44 Cr | 0.6609 | 1.64 Cr | 43.46 Cr | 26.15 Cr | 19.17 Cr | 33.59 | 37.61 Cr | 0.0602 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 5.44 Cr | 497.99 Cr | 115.01 Cr | 382.9810 Cr | 3.32 Cr | -2.11 Cr | 43.61 Cr | 88.28 Cr | 3.24 Cr | 0.00 Cr | 32.84 Cr | 99.0476 Cr |
| 2023-03-31 | 1.45 Cr | 423.39 Cr | 111.83 Cr | 311.5676 Cr | 5.32 Cr | 3.87 Cr | 50.68 Cr | 80.28 Cr | 58.73 Cr | -3.97 Cr | 29.88 Cr | 98.9375 Cr |
| 2022-03-31 | 2.28 Cr | 402.84 Cr | 123.37 Cr | 279.4711 Cr | 5.66 Cr | 3.39 Cr | 39.18 Cr | 84.62 Cr | 70.12 Cr | 0.00 Cr | 55.55 Cr | 108.9432 Cr |
| 2021-03-31 | 5.08 Cr | 341.40 Cr | 97.02 Cr | 244.3820 Cr | 1.62 Cr | -3.46 Cr | 35.75 Cr | 83.24 Cr | 44.63 Cr | 0.00 Cr | 28.86 Cr | 80.6091 Cr |
| 2020-03-31 | 6.42 Cr | 320.22 Cr | 97.42 Cr | 222.7979 Cr | 2.05 Cr | -4.37 Cr | 42.72 Cr | 90.29 Cr | -2.17 Cr | 0.00 Cr | 24.17 Cr | 80.9788 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 45.5022 Cr | -39.1078 Cr | -8.2699 Cr | 34.6282 Cr | 3.9935 Cr | 5.4389 Cr | -10.8740 Cr | 75.4201 Cr | -1.8690 Cr | -5.1691 Cr | 7.0704 Cr |
| 2023-03-31 | 10.5150 Cr | -4.9952 Cr | -6.3622 Cr | 5.2781 Cr | -0.8308 Cr | 1.4454 Cr | -5.2369 Cr | 50.7354 Cr | 0.2032 Cr | -5.1498 Cr | -11.5033 Cr |
| 2022-03-31 | 40.3647 Cr | -39.6973 Cr | -4.8801 Cr | 29.2833 Cr | -4.1323 Cr | -1.4895 Cr | -11.0814 Cr | 47.2976 Cr | -1.1557 Cr | -3.4358 Cr | -3.4311 Cr |
| 2021-03-31 | 36.6107 Cr | -36.6844 Cr | -1.7050 Cr | 34.9786 Cr | -1.7741 Cr | 4.6428 Cr | -1.6321 Cr | 27.4436 Cr | -1.2163 Cr | -0.0402 Cr | 6.9748 Cr |
| 2020-03-31 | 30.0934 Cr | -19.9989 Cr | -10.1699 Cr | 14.6705 Cr | 0.0048 Cr | 6.4169 Cr | -15.4229 Cr | 28.9544 Cr | -0.9192 Cr | -8.8834 Cr | 1.3348 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 83.08 Cr | 26.34 Cr | 56.75 Cr | 0.6830 | -1.03 Cr | -9.39 Cr | -16.45 | -8.34 Cr | -0.1130 |
| 2024-09-30 | 98.44 Cr | 30.32 Cr | 68.12 Cr | 0.6920 | 4.55 Cr | 18.07 Cr | 31.67 | 26.86 Cr | 0.1836 |
| 2024-06-30 | 89.36 Cr | 30.30 Cr | 59.06 Cr | 0.6609 | 30.69 Cr | 18.84 Cr | 33.02 | 23.94 Cr | 0.2109 |
| 2024-03-31 | 89.06 Cr | 54.20 Cr | 34.86 Cr | 0.3914 | 7.74 Cr | 12.91 Cr | 22.63 | 20.01 Cr | 0.1450 |
| 2023-12-31 | 88.28 Cr | 32.80 Cr | 55.48 Cr | 0.6285 | 23.55 Cr | 18.72 Cr | 32.80 | 25.24 Cr | 0.2120 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 3.70 Cr | 318.59 Cr | 322.29 Cr | 0.00 Cr | 47.48 Cr | 416.15 Cr | 95.32 Cr | 535.33 Cr | 122.10 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 285.23 Cr | 0.00 Cr | 0.00 Cr | 285.23 Cr | 0.00 Cr | 0.00 Cr | -382.98 Cr |
| 2024-03-31 | 31.16 Cr | 254.30 Cr | 285.46 Cr | 29.33 Cr | 43.61 Cr | 371.63 Cr | 88.28 Cr | 497.99 Cr | 115.01 Cr |
| 2023-12-31 | -222.87 Cr | 445.74 Cr | 222.87 Cr | 0.00 Cr | 0.00 Cr | 222.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 4.83 Cr | 233.41 Cr | 238.24 Cr | 32.47 Cr | 39.80 Cr | 324.13 Cr | 85.76 Cr | 454.55 Cr | 104.26 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 18.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 12.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 18.72 Cr | 3.37 Cr | 0.00 Cr | 0.00 Cr | 3.37 Cr | 20.44 Cr | 17.07 Cr | 0.00 Cr | 3.37 Cr |
| 2023-09-30 | 20.30 Cr | 2.92 Cr | 0.00 Cr | 0.00 Cr | 2.92 Cr | 17.07 Cr | 14.16 Cr | 0.00 Cr | 2.92 Cr |
| 2023-06-30 | 23.49 Cr | 3.71 Cr | 0.00 Cr | 0.00 Cr | 3.71 Cr | 5.42 Cr | 1.71 Cr | 0.00 Cr | 3.71 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,748.00 | ₹4,193,941,440,000.00 | ₹1,148,922.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,045.00 | ₹1,604,760,105,000.00 | ₹449,981.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,140.00 | ₹1,062,717,300,000.00 | ₹535,042.00 |
| Mankind Pharma Limited | MANKIND | ₹2,404.00 | ₹991,838,762,080.00 | ₹567,777.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,158.10 | ₹964,828,188,462.00 | ₹1,248,300.00 |
| Lupin Limited | LUPIN | ₹2,035.00 | ₹929,215,595,000.00 | ₹558,111.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹880.90 | ₹886,388,007,000.00 | ₹783,082.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,159.80 | ₹673,614,159,600.00 | ₹645,512.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,950.00 | ₹591,846,750,000.00 | ₹53,048.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,393.00 | ₹393,105,993,000.00 | ₹479,938.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,356.00 | ₹344,022,624,000.00 | ₹153,297.00 |
| Laurus Labs Limited | LAURUSLABS | ₹589.05 | ₹317,646,979,650.00 | ₹1,383,505.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,531.10 | ₹316,164,763,200.00 | ₹45,303.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,076.90 | ₹274,141,048,500.00 | ₹138,631.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,524.00 | ₹237,251,748,000.00 | ₹135,150.00 |
| Piramal Enterprises Limited | PEL | ₹1,012.10 | ₹228,206,283,800.00 | ₹661,159.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹7,993.00 | ₹199,825,000,000.00 | ₹14,627.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,228.30 | ₹199,572,955,700.00 | ₹413,280.00 |
| Eris Lifesciences Limited | ERIS | ₹1,459.00 | ₹198,693,915,000.00 | ₹113,370.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹896.55 | ₹176,228,557,650.00 | ₹93,847.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,363.00 | ₹158,616,053,700.00 | ₹41,048.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹810.20 | ₹145,114,922,000.00 | ₹453,167.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,860.00 | ₹141,381,762,000.00 | ₹62,202.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹863.00 | ₹137,459,503,000.00 | ₹128,164.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹441.95 | ₹107,192,320,800.00 | ₹1,886,979.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,045.00 | ₹83,743,973,000.00 | ₹5,996.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹773.00 | ₹70,060,561,260.00 | ₹487,812.00 |
| FDC Limited | FDC | ₹430.00 | ₹70,008,300,000.00 | ₹84,454.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹638.95 | ₹62,483,495,555.00 | ₹133,815.00 |
| Strides Pharma Science Limited | STAR | ₹639.30 | ₹58,919,614,110.00 | ₹149,838.00 |
| Innova Captab Limited | INNOVACAP | ₹849.50 | ₹48,612,578,035.00 | ₹198,796.00 |
| Hikal Limited | HIKAL | ₹385.35 | ₹47,514,040,350.00 | ₹199,111.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹141.31 | ₹45,858,203,820.00 | ₹337,923.00 |
| Sequent Scientific Limited | SEQUENT | ₹160.98 | ₹40,293,615,960.00 | ₹1,484,319.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹778.00 | ₹39,459,459,800.00 | ₹21,883.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹560.00 | ₹39,427,248,000.00 | ₹31,585.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹423.00 | ₹38,607,210,000.00 | ₹570,318.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹355.00 | ₹35,598,690,000.00 | ₹51,448.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,042.00 | ₹33,772,638,000.00 | ₹9,278.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹57.00 | ₹31,233,378,000.00 | ₹7,592,577.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.01 | ₹30,968,688,740.00 | ₹870,137.00 |
| Alembic Limited | ALEMBICLTD | ₹98.80 | ₹25,370,061,501.00 | ₹279,135.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹502.50 | ₹24,146,632,500.00 | ₹75,590.00 |
| Indoco Remedies Limited | INDOCO | ₹240.00 | ₹22,139,496,000.00 | ₹38,062.00 |
Key Executives
Executive Chairman
Mr. Arun Kumar Kothari
Gender: male
Year Born: 1953
General Manager of Sales & Marketing
Dr. Nandraj Patil
Gender: Not Specified
Year Born:
Plant Head - Kolkata
Mr. Santanu Bhattacharya
Gender: male
Year Born: 1969
Head of Sales Training
Mr. Siddesh Rege
Gender: male
Year Born:
Head of Operations - Ghaziabad
Mr. Chandra B. Thakur
Gender: male
Year Born:
Corporate Head of Human Resource
Mr. Adi Joyti Chattopadhyay
Gender: male
Year Born: 1962
Chief Financial Officer & Chief Investor Relations Officer
Mr. Ranadeep Bhattacharya
Gender: male
Year Born: 1971
MD, Chief Executive Officer & Director
Mr. Umesh Manohar Kunte
Gender: male
Year Born: 1969
FAQs about Albert David Limited
Who is the CEO of the company?
The CEO is Mr. Umesh Manohar Kunte.
What is the current market price of the stock?
The current price is ₹802.80.
What is the 52-week price range?
The range is ₹762.6-1753.95.
What is the market capitalization of the company?
The market capitalization is ₹458.17 crores.
What is the dividend yield?
The dividend yield is 1.43%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 11.33.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Albert David Limited (ISIN: INE155C01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹458.17 crores and an average daily volume of 10,780 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.5.